|Mr. Remi Barbier||Founder, Chairman, Chief Exec. Officer, Pres and Corp. Sec.||1.16M||N/A||58|
|Dr. Nadav Friedmann Ph.D., M.D.||Chief Operating Officer, Chief Medical Officer and Director||462.5k||N/A||75|
|Mr. Michael J. O'Donnell Esq.||Sec. and Director||N/A||N/A||60|
|Dr. Michael Marsman Pharm.D.||Sr. VP of Regulatory Affairs||N/A||N/A||N/A|
Pain Therapeutics, Inc., a biopharmaceutical company, develops drugs for treating nervous system in the United States. The company's lead drug candidate is REMOXY, a proprietary abuse-deterrent oral formulation of oxycodone for pain relief. It also develops FENROCK, a proprietary abuse-deterrent transdermal pain patch for pain relief; and PTI-125, a small molecule drug candidate to treat Alzheimer's disease and other neurological disorders. The company was founded in 1998 and is based in Austin, Texas.
Pain Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.